MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer, who will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer and John Leasure, Global Commercial Officer. They will be available to answer questions from participants following prepared remarks. Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below. CONFERENCE CALL INFORMATIONConference Call DateApril 9, 2025Conference Call Time8:30 a.m. ETWebcast Linkhttps://edge.media-server.com/mmc/p/coipg2gbDial in1-877-513-4119 (toll free) or 1-412-902-6615 (international)Access Code2419339CONFERENCE CALL REPLAYToll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)International Toll1-412-317-0088Replay Access Code5058651Replay End DateApril 16, 2025To access the replay using an international dial-in number, please select this link: https://services.choruscall.com/ccforms/replay.html An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X. Contacts: Investor inquiries: Joanne Choi Senior Director, Investor Relations [email protected] 1-551-261-0401 Media inquiries: Julie Schneiderman Senior Director, Communications & Corporate Affairs [email protected] 1-514-336-7800
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...